| Patent application number | Description | Published |
|---|
| 20080199452 | BOTULINUM TOXIN COMPOSITIONS AND METHODS - Disclosed herein are methods of using extracellular matrix digesting enzymes and neurotoxins, such as a Clostridial neurotoxins, to treat various medical conditions, such as overactive bladder, benign prostatic hyperplasia, hyperhidrosis, for example. | 08-21-2008 |
| 20080199453 | BOTULINUM TOXIN COMPOSITIONS AND METHODS - Disclosed herein are methods of using extracellular matrix digesting enzymes and neurotoxins, such as a | 08-21-2008 |
| 20090252764 | SUTURE LINE ADMINISTRATION TECHNIQUE USING BOTULINUM TOXIN - The present invention utilizes patient-specific landmarks in order to treat headache pain. In one aspect, the present invention relates to the administration of Clostridial toxins, such as a botulinum neurotoxin, to a patient suffering from a headache pain, where the location of administration of the botulinum toxin is based upon at least one suture line of the patient's skull. | 10-08-2009 |
| 20100124559 | Early Treatment and Prevention of Increased Muscle Tonicity - Described herein are methods of preventing, modulating and treating spasticity and maladaptive neuronal plasticity in patients having upper motor neuron lesions or have had a traumatic central nervous system event by early intervention methods. The methods comprise the step of administering a therapeutically effective amount of a botulinum toxin or derivative thereof to least a portion of a 1A sensory afferent of at least one muscle prior to development of spasticity or maladaptive neuronal plasticity becomes clinically apparent. The therapeutically effective amount of botulinum toxin administered to the 1A afferent of the muscle does not substantially affect the Golgi tendons therein. | 05-20-2010 |
| 20110200639 | Botulinum toxin treatments of Depression - Methods for preventing or treating depression including a depression mediated by the thalamus. Depression, including a thalamically mediated depression, can be treated by peripheral administration of a | 08-18-2011 |
| 20120040911 | TARGETED DELIVERY OF BOTULINUM TOXIN FOR THE TREATMENT AND PREVENTION OF TRIGEMINAL AUTONOMIC CEPHALGIAS, MIGRAINE AND VASCULAR CONDITIONS - Botulinum toxin, among other presynaptic neurotoxins is used for the treatment and prevention of migraine and other headaches associated with vascular disorders. Presynaptic neurotoxins are delivered focally, targeting the nerve endings of the trigeminal nerve, the occipital nerve and the intranasal terminals of the parasympathetic fibers originating in the Sphenopalatine ganglion. The administration preferably targets the extracranial nerve endings of the trigeminal nerve in the temporal area, the extracranial occipital nerve endings in the occipital area, and the intranasal terminals of the trigeminal nerve and parasympathetic fibers originating in the Sphenopalatine ganglion. The delivery is carried out by way of injection or topically. | 02-16-2012 |
| 20120244188 | Treatment of Sensory Disturbance Disorders - The present specification discloses methods of treating a sensory disturbance disorder in an individual using Targeted Endopeptidase Modulators (TEMs), compositions comprising such TEMs, compositions comprising such TEMs and Clostridial toxins, use of such TEMs and/or Clostridial toxins in manufacturing a medicament for treating a sensory disturbance disorder, use of such TEMs and Clostridial toxins in manufacturing a medicament for treating a sensory disturbance disorder, use of such TEMs in treating a sensory disturbance disorder, and use of such TEMs and Clostridial toxins in treating a sensory disturbance disorder. | 09-27-2012 |
| 20120245096 | TARGETED DELIVERY OF BOTULINUM TOXIN FOR THE TREATMENT AND PREVENTION OF TRIGEMINAL AUTONOMIC CEPHALGIAS, MIGRAINE AND VASCULAR CONDITIONS - Botulinum toxin, among other presynaptic neurotoxins is used for the treatment and prevention of migraine and other headaches associated with vascular disorders. Presynaptic neurotoxins are delivered focally, targeting the nerve endings of the trigeminal nerve, the occipital nerve and the intranasal terminals of the parasympathetic fibers originating in the Sphenopalatine ganglion. The administration preferably targets the extracranial nerve endings of the trigeminal nerve in the temporal area, the extracranial occipital nerve endings in the occipital area, and the intranasal terminals of the trigeminal nerve and parasympathetic fibers originating in the Sphenopalatine ganglion. The delivery is carried out by way of injection or topically. | 09-27-2012 |
